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Abstract  
Background: Attention-deficit/hyperactivity disorder (ADHD) and bipolar disorder (BPD) are 
frequently co-occurring and highly heritable mental health conditions. We hypothesized that BPD 
cases with an early age of onset (≤21 years) would be particularly likely to show genetic covariation 
with ADHD.  
Methods: GWAS data were available for 4,609 individuals with ADHD, 9,650 individuals with BPD 
(5,167 thereof with early-onset BPD) and 21,363 typically developing controls. We conducted a cross-
disorder GWAS meta-analysis to identify whether the observed comorbidity between ADHD and BPD 
could be due to shared genetic risks. 
Results: We found a significant SNP-based genetic correlation between ADHD and BPD in the full 
and age-restricted samples (rGfull = 0.64, p = 3.13×10-14; rGrestricted = 0.71, p = 4.09×10-16). The meta-
analysis between the full BPD sample identified two genome-wide significant (prs7089973 = 2.47×10-8; 
prs11756438 = 4.36×10-8) regions located on chromosomes 6 (CEP85L) and 10 (TAF9BP2). Restricting 
the analyses to BPD cases with an early onset yielded one genome-wide significant association 
(prs58502974 = 2.11x10-8) on chromosome 5 in the ADCY2 gene. Additional nominally significant regions 
identified contained known eQTLs with putative functional consequences for NT5DC1, NT5DC2 and 
CACNB3 expression, while functional predictions implicated ABLIM1 as an allele-specifically 
expressed gene in neuronal tissue.  
Conclusions: The SNP-based genetic correlation between ADHD and BPD is substantial, significant, 
and consistent with the existence of genetic overlap between ADHD and BPD, with potential 
differential genetic mechanisms involved in early and later BPD onset. 
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Introduction  
Attention-deficit/hyperactivity disorder (ADHD) is the most frequent neuropsychiatric 
disorder in childhood and frequently persists into adulthood. Bipolar disorder (BPD) is amongst the 
most prevalent mental diseases in adulthood. Both disorders are highly heritable (1, 2). However, in 
both cases the mode of inheritance is complex and polygenic (3). Although differing from one another 
with regard to core signs and symptoms, age of onset, presentation and treatment response, the two 
disorders share several clinical features. This is especially the case for the manic phase of BPD, which 
is associated with irritability, increased impulsivity, distractibility, and restlessness (4). Furthermore, 
ADHD often co-presents with depression (5), a core feature of BPD. In adulthood, when BPD is most 
commonly diagnosed, co-occurrence of the two disorders occurs more often than would be expected 
by chance (6). For patients with BPD rates of ADHD vary between 9.5% and 28%, depending on 
study characteristics (7, 8). The rate of BPD in adult ADHD has been estimated at around 20% (7). 
Meta-analyses of family studies confirm elevated rates of BPD in first-degree relatives of ADHD 
patients and vice versa (8).   
Although a shared genetic basis for ADHD and BPD seems plausible given the above, 
molecular genetic studies thus far provide limited evidence for this (9-11). For instance, risk allele 
frequencies of candidate genes, identified through prior ADHD genome-wide association studies, are 
not increased in BPD. This failure to find a shared genetic signal may be due to prior studies’ lack of 
statistical power, and the limited set of polymorphisms examined. To address these shortcomings, a 
genome-wide cross-disorder meta-analysis of BPD and ADHD was conducted in a large sample of 
individuals with BPD, with ADHD and typically developing controls from the Psychiatric Genomics 
Consortium. Because ADHD is a childhood onset disorder (prior to 12 years), we hypothesized that 
the overlap would be most obvious in BPD cases with a relatively early onset (age of onset ≤21 years), 
as this group could be assumed to have a more neuro-developmental etiology (8). Restricting the age 
range of the sample to those with an onset ≤21 years may also increase the power for gene-finding 
since it could reduce heterogeneity (12). We thus performed analyses with the total number of BPD 
cases as well as the age-restricted set. GWAS meta-analysis top-findings were further characterized 
using eQTL analysis to investigate potential functional consequences for gene expression.  
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Methods and Materials 
Samples 
Cases, controls, and family-based samples assembled for previous genome-wide PGC analyses 
of individual-level data were included in the current analysis (13, 14). A description of individual 
study data contributions and genotyping platforms is included in the Supplemental Tables S1a and 
S1b. The ADHD sample comprised 4,609 cases and 8,519 controls. The full BPD sample comprised 
9,650 cases and 12,844 controls. For tests of the age of onset hypothesis we restricted the BPD sample 
to cases with an age of onset ≤21 years of age. This reduced the number of cases to 5,167 (restricted 
sample). All available controls from the BPD samples were included in the age restricted sample to 
maximize power. Control individuals that featured in both the ADHD and BPD samples were 
identified and removed prior to analysis. 
 
Genetic Analysis 
Raw genotype and phenotype data for each study was uploaded to a central server and 
processed through the same quality control, imputation, and analysis process to ensure comparability 
between the samples. The quality control and analysis pipeline is described elsewhere (3).  
 
Statistical analysis 
Linkage disequilibrium score regression (LDSR) was used to estimate the SNP-based genetic 
correlation (rG) between ADHD and both BPD samples. For LDSR, each data set underwent additional 
filtering. Only markers overlapping with HapMap Project Phase 3 SNPs and passing the following 
filters were included: INFO score > 0.9, study missingness of 0 and MAF > 1% (where available). 
Indels and strand-ambiguous SNPs were removed.  
The analysis was conducted using a two-step procedure with the LD-scoring analysis package 
(Bulik-Sullivan et al., 2015). An unconstrained regression was run to estimate the regression intercepts 
for each phenotype, followed by an analysis with regression intercepts constrained to those estimated 
in the first step and an unconstrained covariance intercept (we took steps to exclude overlapping 
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samples). Standard errors were estimated using a block jackknife procedure and used to calculate P-
values. 
GWAS was initially performed for each ADHD study separately (n=8). Four multidimensional 
scaling components were included to account for potential population stratification. GWAS was then 
also performed for each BPD study separately (n=12). In this case a total of seven multidimensional 
scaling components (both total and restricted samples). These GWAS were free from genomic 
inflation as judged by quantile-quantile plots (data not shown). For each disorder, results were then 
combined in a disorder-specific meta-analysis. Finally, results from the disorder-specific meta-
analyses were combined in cross-disorder meta-analyses for both the primary and the age-restricted 
samples. For all meta-analyses, we applied a weighted Z-score approach using Plink 1.07, in which 
weights equaled the inverse of the regression coefficient’s standard error (15). This strategy assumed a 
fixed-effects model, in which all studies/disorders had the same direction of effect, with weights 
indicating the sample size and imputation accuracy of the disease-specific studies. The fixed effects 
model was compared to a genome-wide random-effects model, in which studies/disorders were 
allowed to have a different direction of effect. 
 
Prediction of allele-specific effects on transcription  
The overlap between polymorphic loci with miRNA binding sites was examined suing the 
PolymiRTS 3.0 database (16). To check for the known influence of identified SNPs on gene 
expression, we searched a database of cis-acting eQTLs defined with RNA-seq data of lymphoblastoid 
cell lines from 462 individuals, most of which were also examined in the 1000 Genomes Phase I 
dataset (17). Allele-specific transcription factor binding sites (TFBS) were predicted with the web-
based tool MatInspector version 2.1 (18). TFBS searches were performed for all promoter regions (40 
kb upstream) of the top-100 SNPs identified in the full and the age-restricted meta-analyses (i.e. each 
allele flanked by 10 bp up- and downstream sequence). Sequences with a transcription factor-specific 
matrix core similarity of at least 0.75 were defined as potentially containing the respective TFBS.  
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Results 
SNP-Based Genetic Correlation 
The SNP-based rG between ADHD and BPD was substantial and significant for both the full and age-
restricted samples. Interestingly, the rG was higher for the age restricted as compared to the full sample 
(rGfull = 0.64, SE= 0.02, p = 3.13×10-14; rGrestricted = 0.71, SE= 0.02, p = 4.09×10-16; Table 1).  
Full sample  
Figure 1A shows the Manhattan plot of the primary cross-disorder meta-analysis and Figure 
S1A shows the corresponding QQ plot. Two independent loci, located on chromosomes 6 and 10, 
reached genome-wide significance (p<5×10-8). The strongest signal (p = 2.47×10-8) was for SNP 
rs7089973, located on chromosome 10 in an intronic region of the TAF9B RNA polymerase II, TATA 
box binding protein (TBP)-associated factor, 31kDa pseudogene 2 gene (TAF9BP2; Figure 2A) which 
is a pseudogene of yet unknown function. SNP rs7089973 is in linkage disequilibrium (LD) with SNPs 
in the TruB Pseudouridine (Psi) Synthase Homolog 1 gene (TRUB1; best p = 8.89×10-6) and with the 
family with sequence similarity 160 member B1 gene (FAM160B1; best p = 5.45×10-8).  
On chromosome 6, the strongest signal was for SNP rs11756438, located in an intronic region 
of the centrosomal protein 85kDa-like gene (CEP85L; p = 4.36×10-8; Figure 2B) encoding a protein 
of unknown function. Furthermore, rs11756438 is in LD with SNPs in the Bromodomain Containing 7 
Pseudogene 3 gene (BRD7P3; best p = 9.39×10-7), the phospholamban gene (PLN; best p = 7.25×10-7), 
and the Solute Carrier Family 35, Member F1 gene (SLC35F1; best p = 1.00×10-5). Both associated 
regions showed the same direction of effect in ADHD and BPD. The disorder-specific contribution to 
each genome-wide significant locus can be found in Table 2, and forest plots from individual GWAS 
are shown in Figure S5. Top-ranked SNPs for this analysis (p < 10-6) are summarized in Table S3.  
 
Age-Restricted BPD sample  
The Manhattan plot for the age-restricted analysis is shown in Figure 1B; the respective QQ 
plot is provided in Figure S1B. One SNP on chromosome 5 reached genome-wide significance; forest 
plots of results from individual GWAS are shown in Figure S5. The strongest signal (p = 2.47×10-8) 
was observed for SNP rs58502974, located in an intron of the Adenylate Cyclase 2 (Brain) (ADCY2) 
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gene (Figure 2C). The product of this gene is a member of the family of adenylate cyclases, which are 
membrane-associated enzymes that catalyze the formation of the secondary messenger cyclic 
adenosine monophosphate (cAMP). Top-ranked SNPs for this analysis (p < 10-4) are summarized in 
Table S3.  
 
Allele-specific transcriptional activity 
None of the top-100 associated SNPs in the primary and restricted analyses (Supplemental 
Table S3) were listed in the Geuvadis database of cis-eQTLs defined in lymphoblastoid cell lines that 
were mainly derived from the 1000 Genomes sample (17). To estimate the potential eQTL function in 
other tissues, direct bioinformatics prediction was thus used and found differential binding of 
transcription factors for 13 markers in the primary and four in the restricted GWAS, which involved 
neuro-relevant transcription factors at seven and one sites, respectively (Supplemental Table S5). A 
notable finding among those was for the gene ABLIM1. Allele-specific binding sites of miRNAs at the 
3’-UTR of family with sequence similarity 160, member B1 (FAM160B1) transcripts were also 
observed (Supplemental Table S5). 
Extending this analysis to evaluate top-ranked SNPs (p < 10-4) for effects on transcriptional 
activity, we queried the Geuvadis database (17) for known eQTLs. Of the 4,806 SNPs displaying a 
trend towards association (p<1×10-4) in one of the two analyses, 192 indeed were known eQTLs 
(Supplemental Table S4). Of those, 74 markers influenced the expression of 5'-nucleotidase domain 
containing 2 (NT5DC2); the expression of its homolog NT5DC1 was modulated by 17 SNPs. Two 
SNPs were found to influence the expression of the calcium channel, voltage-dependent, beta 3 
subunit (CACNB3). The accumulation of eQTLs at the NT5DC loci especially may be explained by 
LD. Indeed, when we tested the total number of eQTLs, it did not exceed expectation in either the full 
or the restricted analysis (ORprimary=0.91, pprimary=0.27; ORrestricted=0.97, pprestricted=0.84).  
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Discussion 
In this study, we set out to identify shared genetic risk factor for ADHD and BPD through 
cross-disorder meta-analysis of the existing GWAS samples from the Psychiatric Genomics 
Consortium. We hypothesized that overlap between the disorders might be most pronounced in BPD 
cases with an early age of onset, and that restricting the analysis to samples with an onset ≤21 would 
increase the power of gene-finding by reducing heterogeneity (8). Our findings clearly show the 
substantial and significant genetic correlation between ADHD and BPD which supports the existence 
of genome-wide significant, shared genetic risk variants for ADHD and BPD (rGfull = 0.64, SE= 0.08, p 
= 3.13×10-14; rGrestricted = 0.71, SE= 0.09, p = 4.09×10-16; Table 1). We contrasted these results by 
estimating the genetic correlation between ADHD and BPD using previously published data sets and 
found the same correlation pattern (Supplemental Table S2). 
In the full sample, we found two genome-wide significant loci and 10 with suggestive 
evidence of association (p<10-6; Supplemental Table S3). Although the statistical power was 
potentially lower in the age-restricted sample, one significant finding was observed. The region 
identified was different from the top-findings in the primary analysis, raising the possibility of 
development-specific gene activity in these two conditions. When specifically considering the BPD 
analyses (Table S3, also compare Figure S2A with S2B), it becomes clear that almost all top cross-
disorder SNPs have lower p values in the age-restricted BPD sample as compared to the full BPD 
sample, despite its lower power. This might point to a stronger genetic component of early-onset BPD 
and consequently a different etiology as compared to late-onset BPD (19). However, these findings are 
still preliminary addressing this issue was not the major aim of our analysis and further work is clearly 
needed to adequately answer such questions. 
Our top hit in the full analysis was present on chromosome 10 in the gene TAF9BP2. This 
being a pseudogene of unknown function, we cannot speculate about its potential involvement in the 
ADHD-BPD covariation. TRUB1, which includes variants in LD with the top SNP may constitute a 
potential candidate gene; its product is a member of the pseudouridine synthase gene family and may 
function as RNA chaperone, altering aspects of mRNA metabolism known to be affected by RNA 
structure (20). The protein encoded by CEP85L, suggested to be involved by the hit on chromosome 6, 
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was identified as a breast cancer antigen (21); the gene was also associated in a meta-analysis with the 
myocardial repolarization (22, 23), the latter lending some support to the notion that the gene’s 
product is involved in neural conduction. This is the first time that genes in these loci are associated 
with psychiatric diseases, so the mechanisms by which variants in those might affect disease risk 
remain elusive. Our eQTL analyses did not provide evidence for a direct effect of the variation on the 
expression of the implicated genes or surrounding genes in LD with the hits. Furthermore, the 
functions of these genes are not well described, highlighting the need for further research. 
The best hit found in the age-restricted sample is more obviously functionally significant. 
ADCY2, which codes for adenylate cyclase 2, is a key regulator of cyclic AMP metabolism and thus of 
second messaging by activating PKA, thereby triggering CREB phosphorylation (24). Both the PKA 
and CREB pathways (25, 26) have been implicated in BPD, and CREB1 is a well-documented 
candidate gene for BPD (27). Recently, a SNP in ADCY2 was also found to be genome-wide 
significantly associated with BPD (28). There is a vast literature on disturbances of serotonin and 
dopamine signaling in ADHD; both monoamines target G-protein coupled receptors (GPCRs) that use 
ADCY2 in their signal transduction cascades, so it is conceivable that this protein is also relevant to 
ADHD. As this association became significant (p=4.5×10-8) when restricting the BPD sample to an 
age of onset ≤21 years, the signal likely may be associated with a more neuro-developmental form of 
BPD. One hypothesis for future research is that adenylate cyclase signaling is a core mechanism 
mediating the comorbidity between ADHD and BPD. 
Our primary meta-analysis yielded 10 suggestive loci (p<10-6). In addition to the 
aforementioned genes, these loci comprise the following candidate genes, each supported by at least 
three suggestive associations: On chromosome 1, we observed a suggestive association with the 
retinoid X receptor, gamma gene (RXRG). RXRG codes for retinoid receptor gamma - a regulator of 
dopamine signaling, cocaine response, and affective behaviors in mice (29, 30). This makes it an 
attractive candidate for both BPD and ADHD. The gene has been suggested to have an effect on 
hippocampal volume by QTL analysis in mice (31) and has been associated with sensation seeking 
(32), a personality trait associated with combined-type ADHD (33). On chromosome 3, a signal for the 
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neuroligin 1 (NLGN1) gene was also found. The neuroligin protein family has already been implicated 
in a wide range of neuropsychiatric disorders including autism, schizophrenia, and BPD (34).  
Presence of eQTLs was evaluated in SNPs with association p-values <10-4 in either of the 
cross-disorder GWAS meta-analyses (Supplemental Table S5). Several interesting candidate genes 
for ADHD-BPD covariation were found to be regulated by multiple SNPs in our list serving as 
eQTLs. Of greatest interest are the findings implicating two members of the NT5DC family, a family 
of haloacid dehalogenase (HAD)-type phosphatases (35). NT5DC1 has been associated with BPD in 
several studies, showing the strongest association with the disorder in NIMH Genetics Initiative 
bipolar pedigrees (36). Importantly, we recently observed an association between rare variants in this 
gene and adult ADHD (under review). NT5DC2 has previously been found associated with 
schizophrenia; furthermore, NT5DC2 is a target of miR-137 and is differentially methylated as a 
function of childhood maltreatment in BPD patients (37). Another interesting finding was for 
CACNB3, which codes for a voltage-gated calcium channel involved in neuronal morphology and 
differentiation; its transcript is targeted by miR-34a, which is upregulated in cerebellum of bipolar 
patients (38). Allelic variation in ABLIM1, which has previously been associated with novelty seeking, 
harm avoidance, reward and alcohol dependence (39), also appears to be a plausible finding. 
Our finding that putative promoter regions containing the top-ranked associated SNPs do not contain 
known eQTLs was against our predictions of allele-specific effects on transcription. This discordance 
may, on the one hand, be attributed to the known high false positive rate of pattern searches with 
position-specific scoring matrices (18). On the other hand, the eQTL dataset was derived from 
analyses of lymphoblastoid cell lines (17), and it is therefore conceivable that the allele-specific 
transcription factor binding sites may serve as functional eQTLs in a different tissue context.  
The findings described here need to be interpreted in the light of several caveats: The 
differential diagnosis especially between BPD and adult ADHD can be challenging. While this does 
not affect the ADHD sample, which was ascertained in childhood, it might pose a problem for the 
BPD sample: some shared signals might be due to patients with adult ADHD having falsely received a 
diagnosis of BPD. Given that all studies included here relied on DSM inclusion criteria, we are 
confident that misdiagnosis is at least not common enough to account for genome-wide significant 
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hits. Ethnic heterogeneity might influence the results as well, although we aimed to control for this by 
including MDS components in every GWAS included in the meta-analyses. Finally, sample sizes in 
our cross-disorder analyses were still rather small for complex genetic traits. This was particularly 
damaging in the restricted analysis, where the reduction in sample size masked the potential increase 
in power due to the reduction in etiological heterogeneity (discussed above).  
  In conclusion, we provide evidence for the genetic overlap between ADHD and BPD. This 
genome-wide SNP-based genetic overlap (40) confirms the involvement of pathways such as G-
protein-coupled signaling already known for their role in hyperactivity and/or emotional behaviors, 
and implicate a new candidate pathway (i.e. mRNA stability) in the pathophysiology of both ADHD 
and BPD.  
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